Terms: = Germ cell tumor AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Treatment
284 results:
1. Trauma plays an important role in acral melanoma: A retrospective study of 303 patients.
Huang R; Zhao M; Zhang G; Yang Y; Wang J; Zheng K; Li L; Su X; Zhao L; Wu Y; Zou Z
Cancer Med; 2024 Apr; 13(7):e7137. PubMed ID: 38545846
[TBL] [Abstract] [Full Text] [Related]
2. Glioblastoma Therapy: Past, Present and Future.
Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
[TBL] [Abstract] [Full Text] [Related]
3. CD133 significance in glioblastoma development: in silico and in vitro study.
Abdoli Shadbad M; Nejadi Orang F; Baradaran B
Eur J Med Res; 2024 Mar; 29(1):154. PubMed ID: 38448914
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ; Glassee N; Kicinski M; Blank CU; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Giacomo AMD; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Gandini S; Buhrer E; Suciu S; Robert C; Eggermont AMM; Mandala M; Lorigan P; Valpione S
Eur J Cancer; 2024 Apr; 201():113585. PubMed ID: 38402687
[TBL] [Abstract] [Full Text] [Related]
5. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.
Zhong N; Yu D; Yang M; Lu X; Zhang Q; Wei W; Jiao J; Yang X; Zhu Z; Chen S; Xiao J
J Cancer Res Clin Oncol; 2024 Feb; 150(2):95. PubMed ID: 38369555
[TBL] [Abstract] [Full Text] [Related]
6. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
Shirai Y; Ueno T; Kojima S; Ikeuchi H; Kitada R; Koyama T; Takahashi F; Takahashi K; Ichimura K; Yoshida A; Sugino H; Mano H; Narita Y; Takahashi M; Kohsaka S
J Neurooncol; 2024 Mar; 167(1):75-88. PubMed ID: 38363490
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of Autophagy Aggravates
Tsai CH; Huang HC; Lin KJ; Liu JM; Chen GL; Yeh YH; Lu TL; Lin HW; Lu MT; Chu PC
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279345
[TBL] [Abstract] [Full Text] [Related]
8. Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma.
Lorenzo-Guerra SL; Codina-Martínez H; Suárez-Fernández L; Cabal VN; García-Marín R; Riobello C; Vivanco B; Blanco-Lorenzo V; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201285
[TBL] [Abstract] [Full Text] [Related]
9. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired cdk4/6 inhibitor resistance in acral lentiginous melanoma.
Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic model for assessing the human glioma cell malignancy grade based on MDM2, MELK, SOX2, cdk4, DR5 and OCT4 gene expression.
Tyagunova EE; Drozd SF; Kalennik OV; Samoylenkova NS; Savchenko EA; Danilov GV; Pavlova GV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):43-51. PubMed ID: 38054226
[TBL] [Abstract] [Full Text] [Related]
11. Immune microenvironment heterogeneity reveals distinct subtypes in neuroblastoma: insights into prognosis and therapeutic targets.
Yang Y; Li H; Zheng D; Li X; Liu H
Aging (Albany NY); 2023 Nov; 15(22):13345-13367. PubMed ID: 38019470
[TBL] [Abstract] [Full Text] [Related]
12. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to cdk4/6 inhibitors in breast cancer.
Kim S; Armand J; Safonov A; Zhang M; Soni RK; Schwartz G; McGuinness JE; Hibshoosh H; Razavi P; Kim M; Chandarlapaty S; Yang HW
Cell Rep; 2023 Nov; 42(11):113198. PubMed ID: 37865915
[TBL] [Abstract] [Full Text] [Related]
13. Palbociclib releases the latent differentiation capacity of neuroblastoma cells.
Ferguson KM; Gillen SL; Chaytor L; Poon E; Marcos D; Gomez RL; Woods LM; Mykhaylechko L; Elfari L; Martins da Costa B; Jamin Y; Carroll JS; Chesler L; Ali FR; Philpott A
Dev Cell; 2023 Oct; 58(19):1967-1982.e8. PubMed ID: 37734383
[TBL] [Abstract] [Full Text] [Related]
14. Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI.
Arnfield EG; Tam L; Pattison DA; Younger J; Chikatamarla VA; Wyld D; Burge M; McCormack L; Ladwa R; Ramsay S
J Nucl Cardiol; 2023 Dec; 30(6):2676-2691. PubMed ID: 37587328
[TBL] [Abstract] [Full Text] [Related]
15. Artichoke as a melanoma growth inhibitor.
Mathew AM; Deng Z; Nelson CJ; Mayberry TG; Bai Q; Lequio M; Fajardo E; Xiao H; Wakefield MR; Fang Y
Med Oncol; 2023 Aug; 40(9):262. PubMed ID: 37544953
[TBL] [Abstract] [Full Text] [Related]
16. A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant.
Tran S; Thomas A; Aliouat I; Karachi C; Lozano F; Mokhtari K; Dehais C; Feuvret L; Carpentier C; Giry M; Doukani A; Lerond J; Marie Y; Sanson M; Idbaih A; Carpentier A; Hoang-Xuan K; Touat M; Capelle L; Bielle F
Neuropathol Appl Neurobiol; 2023 Aug; 49(4):e12928. PubMed ID: 37503540
[TBL] [Abstract] [Full Text] [Related]
17. A Potential Anti-Glioblastoma Compound LH20 Induces Apoptosis and Arrest of Human Glioblastoma cells via cdk4/6 Inhibition.
Wang Y; Li Y; Liu D; Zheng D; Li X; Li C; Huang C; Wang Y; Wang X; Li Q; Xu J
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446710
[TBL] [Abstract] [Full Text] [Related]
18. A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma.
Gureghian V; Herbst H; Kozar I; Mihajlovic K; Malod-Dognin N; Ceddia G; Angeli C; Margue C; Randic T; Philippidou D; Nomigni MT; Hemedan A; Tranchevent LC; Longworth J; Bauer M; Badkas A; Gaigneaux A; Muller A; Ostaszewski M; Tolle F; Pržulj N; Kreis S
Cancer Gene Ther; 2023 Oct; 30(10):1330-1345. PubMed ID: 37420093
[TBL] [Abstract] [Full Text] [Related]
19. Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project.
Tao K; Yamazaki F; Kubo T; Sunami K; Kumamoto T; Arakawa A; Sugiyama M; Watanabe Y; Nakajima M; Shirakawa N; Tanimura K; Koyama T; Hirata M; Sudo K; Tanabe N; Watanabe T; Yoshida T; Kitami M; Yoshida A; Yatabe Y; Nakano Y; Ohira M; Kamijo T; Nakazawa A; Kato M; Ichimura K; Kohno T; Yamamoto N; Hishiki T; Ichikawa H; Ogawa C
JCO Precis Oncol; 2023 Jul; 7():e2200266. PubMed ID: 37410973
[TBL] [Abstract] [Full Text] [Related]
20. Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response.
Randic T; Magni S; Philippidou D; Margue C; Grzyb K; Preis JR; Wroblewska JP; Nazarov PV; Mittelbronn M; Frauenknecht KBM; Skupin A; Kreis S
Cell Rep; 2023 Jul; 42(7):112696. PubMed ID: 37379213
[TBL] [Abstract] [Full Text] [Related]
[Next]
